Removing Immune ‘Brake’ Enhances CAR T-Cell Therapy for Pediatric Bone Cancer

Researchers at St. Jude Children’s Research Hospital have identified a potential strategy to improve CAR T-cell therapy for children with relapsed osteosarcoma, a rare and aggressive bone cancer. By removing a specific gene called Regnase-1 from engineered immune cells, scientists observed enhanced ability to combat tumor growth and spread in laboratory models.

Osteosarcoma is particularly challenging to treat in relapsed cases, with limited effective options available. The study highlights a critical gap in current therapies and suggests that modifying immune cells to remove this gene could address some of these limitations.

Preclinical experiments demonstrated that the altered CAR T-cells were more effective at controlling tumor progression and preventing metastasis to the lungs, a common complication in osteosarcoma. These findings provide a foundation for further investigation and potential clinical application.

The research, published in Cell Reports Medicine, supports the initiation of an early-phase clinical trial to test the approach in patients. The study underscores the importance of refining immunotherapy strategies to improve outcomes for children with this aggressive cancer.

Based on reporting from Medical Xpress (Cancer).

Source: Medical Xpress (Cancer). This article was drafted by AI from that reporting and reviewed by an automated accuracy check before publishing.